# Senti Biosciences (SNTI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SNTI
## Company Profile
- Ticker: SNTI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.255 USD
- Market cap: 30640208.9852 USD
- Last updated: 2026-10-13
## Business Overview
### Gene Circuit Cell Therapy Company
Senti Biosciences uses a proprietary Gene Circuit platform to develop next-generation cell and gene therapies. Its logic-gated designs are intended to increase selective tumor-cell killing while protecting healthy tissue.
### SENTI-202 Logic-Gated CAR-NK
SENTI-202 is an off-the-shelf CAR-NK candidate designed to target hematologic malignancies expressing CD33 and/or FLT3 while using an EMCN NOT gate to protect healthy hematopoietic stem and progenitor cells. An IL-15 release module is intended to improve CAR-NK persistence, expansion, and activity.
### Registrational Path in AML
Senti Bio completed a Type B Initial Comprehensive Multidisciplinary RMAT meeting with the FDA and aligned on pivotal clinical and CMC strategy for SENTI-202. FDA feedback supports the potential use of a single-arm, multicenter pivotal trial in relapsed or refractory AML.
### Allogeneic Manufacturing Strategy
SENTI-202 is being developed as an off-the-shelf product manufactured from selected donor material. Senti’s Donor X strategy is intended to improve consistency in potency, expansion, and clinical activity across production campaigns.
### Logic-Gate Architecture
The OR gate enables recognition of either CD33 or FLT3 on malignant cells, while the EMCN NOT gate is intended to protect healthy hematopoietic cells. This combination illustrates how Senti’s Gene Circuit platform integrates multiple biological signals into a single cell therapy.
## Why The Stock Is Moving

As of Oct 13, 2026, SNTI closed down 20.0% at $0.2550. No new same-company headline was identified in the current news window.

## Future Catalysts

- SENTI-202 is expected to advance into a single-arm, multicenter pivotal trial in relapsed or refractory AML to support potential registration.
- More complete Phase 1 data, particularly efficacy and MRD-negative responses under the Donor X manufacturing strategy, will inform execution of the pivotal program.

## Recent News
- 2026-07-15 11:30 EST — [Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform](https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-e313e317) — Source: Senti Biosciences
- 2026-05-14 12:45 EST — [Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase](https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-reports-first-quarter-2026-financial-results-and-high-bc8c22b2) — Source: Senti Biosciences
- 2026-05-14 12:40 EST — [Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program](https://biopharmsignal.com/news/SNTI/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-b2d7e183) — Source: Senti Biosciences
- 2026-04-13 13:00 EST — [Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026](https://biopharmsignal.com/news/SNTI/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-sessio-2566d28b) — Source: Senti Biosciences
- 2026-04-01 12:45 EST — [Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies](https://biopharmsignal.com/news/SNTI/senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-l-1e4b43e3) — Source: Senti Biosciences